J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan

Introduction: On the basis of the IMpower133 trial, atezolizumab plus carboplatin and etoposide (CE) is approved as first-line treatment for extensive-stage (ES)-SCLC. The J-TAIL-2 study evaluated atezolizumab plus CE in routine clinical practice settings. Methods: J-TAIL-2 was a prospective, multic...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Eisaku Miyauchi, MD, PhD, Makoto Nishio, MD, PhD, Kadoaki Ohashi, MD, PhD, Atsushi Osoegawa, MD, PhD, Eiki Kikuchi, MD, PhD, Hideharu Kimura, MD, PhD, Yasushi Goto, MD, PhD, Junichi Shimizu, MD, PhD, Hiroshige Yoshioka, MD, PhD, Ichiro Yoshino, MD, PhD, Toshihiro Misumi, PhD, Nobuyuki Katakami, MD, PhD, Masahide Oki, MD, PhD, Takashi Kijima, MD, PhD, Kenichi Chikamori, MD, PhD, Kazumi Nishino, MD, PhD, Yuki Kobayashi, MS, Asako Miwa, BA, Misa Tanaka, MS, Akihiko Gemma, PhD
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2025-03-01
Saila:	JTO Clinical and Research Reports
Gaiak:	Extensive-stage small cell lung cancer Atezolizumab Immune checkpoint inhibitor Observational study
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S266636432400153X
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!